Company: PRME
Filing Date: 2025-11-07
Form Type: S-3ASR
Source: 0001628280-25-050428
Chunk: 60

Company: Prime Medicine, Inc.
Filing Date: 2025-11-07
Form: S-3ASR
Chunk 60
---
 and in Part I, Item 1A. “Risk Factors” of our most recent Annual Report on Form 10-K, any subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K we file after the date of this prospectus, as applicable, together with all other information contained in this prospectus and in our filings with the SEC that we have incorporated by reference in this prospectus. If any of the following risks actually occurs, our business, financial condition or results of operations could be adversely affected, which, in turn, could have a negative impact on the price of our common stock. In these circumstances, the market price of our common stock could decline, and you may lose all or part of your investment. Additional risks not presently known to us or that we currently believe are immaterial may also significantly impair our business operations. Please also read carefully the section above titled “Special Note Regarding Forward-Looking Statements.”

Additional Risks Related To Our Common Stock And This Offering

If you purchase shares of common stock in this offering, you may suffer immediate and substantial dilution of your investment.

The price per share of any common stock sold in this offering may exceed the net tangible book value per share of our common stock outstanding prior to this offering. Therefore, if you purchase shares of our common stock in this offering, you may pay a price per share that substantially exceeds our net tangible book value per share after this offering. To the extent shares are issued under outstanding options at exercise prices lower than the price of our common stock in this offering, you will incur further dilution. Assuming that an aggregate of 46,511,627 shares of our common stock are sold at a price of $4.30 per share, the last reported sale price of our common stock on The Nasdaq Global Market on November 4, 2025, for aggregate gross proceeds to us of $200.0 million, and after deducting commissions and estimated aggregate offering expenses payable by us, you will experience immediate dilution of $2.73 per share, representing the difference between our as-adjusted net tangible book value per share as of September 30, 2025 after giving effect to this offering, and the assumed offering price. See the section entitled “Dilution” below for a more detailed illustration of the dilution you would incur if you participate in this offering.

We have broad discretion in the use of any net proceeds from this offering and may use them in ways that you and other stockholders may not approve.